Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Gastric Cancer Therapy Market was valued at USD 3.98 Billion in 2024, and is expected to reach USD 5.70 Billion by 2030, rising at a CAGR of 6.12%. Gastric cancer, a malignancy originating in the stomach lining, requires a multifaceted approach to treatment that includes surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combination treatments. Market growth is primarily fueled by the rising global incidence of gastric cancer, particularly in regions such as East Asia and Latin America, as well as advancements in diagnostic techniques and therapeutic innovations.

Increasing awareness and early detection initiatives have contributed to better clinical outcomes. Precision medicine and the development of biomarker-based therapies are also reshaping the treatment landscape. Despite these advancements, the market faces challenges such as high treatment costs, resistance to therapy, and limited access to cutting-edge care in certain regions. Nonetheless, continuous research, partnerships among pharmaceutical players, and patient-centered care strategies are propelling the market toward more personalized and effective therapeutic solutions.

Key Market Drivers

Rising Incidence of Gastric Cancer

The increasing incidence of gastric cancer is a critical driver of the Global Gastric Cancer Therapy Market. In 2020, over 1.1 million new gastric cancer cases were reported globally, with approximately 770,000 related deaths. The disease is notably more prevalent in males, and Eastern Asia continues to report the highest incidence. Aging populations, lifestyle factors such as smoking and dietary habits, and environmental exposures contribute to the disease’s global rise.

Regions like Japan, China, South Korea, and parts of Latin America and Europe exhibit particularly high prevalence. In India, for example, northeastern districts like Aizawl and Papumpare have recorded alarmingly high age-adjusted rates. As early detection improves and more cases are diagnosed, the demand for effective treatment options has intensified. This trend is driving the expansion of chemotherapy, immunotherapy, and targeted therapy offerings to meet the growing therapeutic needs of patients worldwide.

Key Market Challenges

Limited Treatment Options for Advanced Stages

Advanced-stage gastric cancer presents a major treatment challenge, largely due to its aggressive progression and resistance to conventional therapies. Once the cancer has metastasized, standard treatments such as chemotherapy, targeted therapies, and immunotherapy may lose efficacy due to genetic mutations and immune evasion mechanisms developed by cancer cells.

As a result, treatment outcomes in advanced stages remain limited. Research is increasingly focusing on combination therapies and novel targets to overcome resistance and improve survival rates. Clinical trials are critical in evaluating these innovations and expanding the therapeutic arsenal. However, access to these new treatments is often limited by geographic, economic, and regulatory constraints. Overcoming these hurdles will require coordinated efforts among research institutions, pharmaceutical companies, and regulatory bodies to broaden treatment options and ensure equitable access for patients battling advanced gastric cancer.

Key Market Trends

Immunotherapies Dominance

Immunotherapy is emerging as a dominant force in the Global Gastric Cancer Therapy Market, revolutionizing the traditional treatment approach by leveraging the immune system to fight cancer. Immune checkpoint inhibitors - such as those targeting PD-1, PD-L1, and CTLA-4 - have demonstrated remarkable success in treating patients with advanced gastric cancer. These therapies have led to longer survival and improved quality of life for some patients who previously had limited treatment options.

Their ability to generate durable immune responses has opened up new possibilities, especially when used in combination with chemotherapy or targeted therapy. However, response rates vary, and immune-related adverse events remain a concern. Ongoing research is focused on identifying biomarkers to better predict patient response, optimizing treatment combinations, and reducing side effects. As clinical evidence grows and regulatory approvals expand, immunotherapies are expected to remain central to the evolving landscape of gastric cancer treatment, driving innovation and offering renewed hope for improved patient outcomes.

Key Market Players

• Abbott Laboratories Inc.
• Amgen, Inc.
• Celltrion Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Agilent Technologies Inc.
• AstraZeneca Plc
• Pfizer Inc.
• Eli Lilly & Co.
• GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Gastric Cancer Therapy Market, By Therapy Type:

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Surgery

Gastric Cancer Therapy Market, By End User:

• Ambulatory Surgery Centers
• Hospitals and Specialty Clinics
• Other

Gastric Cancer Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

This product will be delivered within 1-3 business days.